NEW YORK (GenomeWeb) – Admera Health today announced that its PGxOne Plus and OncoGxOne molecular diagnostic tests have been approved for clinical use by the New Jersey Department of Health.

PGxOne is a companion diagnostic test to help predict response to therapy based on the patients' genetics. The gene panel, which assays 25 genes known to determine drug response, is an expanded version of Admera's PGxOne test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.